BioNTech Builds Case for PD-L1/VEGF Bispecific With ... - BioSpace
Dec 11, 2024 · BioNTech on Tuesday revealed Phase Ib/II data for its investigational PD-L1/VEGF bispecific antibody BNT327, touting encouraging response and survival outcomes in …
What can we help you find? - Merck
Sep 26, 2024 · KEYTRUDA, as a single agent, is indicated for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA …
Tumor-specific delivery of clickable inhibitor for PD-L1 …
Nov 15, 2024 · Achieving selective and durable inhibition of programmed death ligand 1 (PD-L1) in tumors for T cell activation remains a major challenge in immune checkpoint blockade …
The role of PD-L1 in patients with non-small cell lung cancer
Oct 31, 2024 · This study aimed to investigate the prognostic value of PD-L1 in patients with NSCLC receiving neoadjuvant immune checkpoint inhibitor plus chemotherapy (CT).
PD-L1 protects tumor-associated dendritic cells from ... - Cell Press
Nov 26, 2024 · Xiao et al. show that PD-L1 on dendritic cells (DCs) plays a crucial role in enhancing the antitumor immune response during immunogenic chemotherapy by preventing …
FDA approves cosibelimab-ipdl for metastatic or locally advanced ...
5 days ago · On December 13, 2024, the Food and Drug Administration approved cosibelimab-ipdl (Unloxcyt, Checkpoint Therapeutics, Inc.), a programmed death ligand-1 (PD-L1) blocking …
U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select …
Nov 7, 2024 · PD-L1 is a widely used biomarker for cancer patient selection for checkpoint inhibitors, a class of cancer drugs representing a $48 billion global market in 2023, led by …
Checkpoint Therapeutics Announces FDA Approval of
4 days ago · UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma. December 13, 2024 18:15 ET | Source: Checkpoint …
Bristol Myers Squibb - Bristol Myers Squibb Statement on …
Sep 26, 2024 · OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) …
PD-L1 at the crossroad between RNA metabolism and …
May 31, 2024 · Recent results show that intracellular PD-L1 plays a role in post-transcriptional regulation through its ability to bind mRNAs and embed in ribonucleoprotein complexes. …
- Some results have been removed